The present invention relates to a new generation of PDT agents based on porphyrin-lanthanide complexes with specific functional groups which can specifically localize on particular tumors, and their PDT processes can be monitored via NIR emission from erbium. In particular, the present invention provides a multi-modal lanthanide-porphyrin PDT agent (Er—R3) that are capable of killing the bladder tumor cells selectivity via 1O2 from porphyrin moiety and affording the fluorescence imaging simultaneously upon Er—R3 binding with the integrin αvβ3 isoform in bladder cancer cells.